Hong Kong stock movement: INNOGEN-B surged 21.10%, with clear capital flow; what is stirring the market sentiment?

Hong Kong Stock Movement INNOGEN-B surged 21.10%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry PAG Biopharma-B had a trading volume of HKD 856 million, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Innovent Biologics fell 0.25%. Based on recent news, On May 18, Innovent Biologics announced the latest R&D progress, focusing on top drug production for tumors, cardiovascular, and metabolic diseases. After this news was released, the market reacted variably, and the stock price slightly declined. On May 19, the company issued a forward-looking statement, indicating that changes in future business, competitive environment, and political, economic, legal, and social conditions may lead to significant differences between actual results and expectations. Investors expressed concerns about future uncertainties, leading to stock price fluctuations. On May 19, the company released original content through PR Newswire, emphasizing the accuracy of information and accountability. Despite the company's efforts to provide accurate information, the market reacted cautiously to the statement, resulting in a slight decline in stock price. The market remains cautious about the prospects of the biopharmaceutical industry. Kangfang Biologics fell 1.58%, with a trading volume of HKD 553 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Market Capitalization in the Industry BeiGene fell 0.29%. Based on recent key news: On May 14, BeiGene announced that its drug, Tisotumab vedotin, received FDA accelerated approval for the treatment of relapsed or refractory mantle cell lymphoma. This approval marks the first new BCL2 inhibitor approved in the U.S. in a decade, driving volatility in BeiGene's stock price. Source: Zhitong Finance On May 11, Citigroup released a research report, raising BeiGene's U.S. stock target price to $453 due to its strong Q1 performance, with total revenue exceeding estimates by 5%. This optimistic rating further influenced the stock price trend. Source: Citigroup Research On May 18, BeiGene's innovative layout in the solid tumor field received widespread attention, providing a new growth curve for early pipelines such as Tisotumab vedotin. Despite fierce competition, the company has formed a product portfolio in multiple areas, enhancing its risk resistance. Source: Wall Street Insight, global pharmaceutical industry patent cliff pressure intensifies